Denali Therapeutics, Inc. (DNLI)
18.00
-0.08
(-0.47%)
USD |
NASDAQ |
Nov 17, 16:00
18.00
0.00 (0.00%)
After-Hours: 20:00
Denali Therapeutics EPS Diluted (Quarterly) : 0.3651 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.3651 |
| June 30, 2026 | -0.681 |
| March 31, 2026 | -0.6882 |
| December 31, 2025 | -0.7326 |
| September 30, 2025 | -0.736 |
| June 30, 2025 | -0.7239 |
| March 31, 2025 | -0.7766 |
| December 31, 2024 | -0.6747 |
| September 30, 2024 | -0.6326 |
| June 30, 2024 | -0.5865 |
| March 31, 2024 | -0.6814 |
| December 31, 2023 | -0.8642 |
| September 30, 2023 | -0.7218 |
| June 30, 2023 | 1.301 |
| March 31, 2023 | -0.8041 |
| December 31, 2022 | -0.7426 |
| September 30, 2022 | -0.8366 |
| June 30, 2022 | -0.478 |
| March 31, 2022 | -0.5316 |
| December 31, 2021 | -0.6161 |
| September 30, 2021 | -0.6948 |
| Date | Value |
|---|---|
| June 30, 2021 | -0.5015 |
| March 31, 2021 | -0.5794 |
| December 31, 2020 | 1.909 |
| September 30, 2020 | -0.5417 |
| June 30, 2020 | -0.5585 |
| March 31, 2020 | -0.5542 |
| December 31, 2019 | -0.5623 |
| September 30, 2019 | -0.4826 |
| June 30, 2019 | -0.6109 |
| March 31, 2019 | -0.4105 |
| December 31, 2018 | 0.7932 |
| September 30, 2018 | -0.3776 |
| June 30, 2018 | -0.59 |
| March 31, 2018 | -0.2644 |
| December 31, 2017 | -0.74 |
| September 30, 2017 | -0.2425 |
| June 30, 2017 | -0.2458 |
| March 31, 2017 | 1.808 |
| December 31, 2016 | -0.2149 |
| September 30, 2016 | -0.3399 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Oncolytics Biotech, Inc. | -0.0759 |
| Sangamo Therapeutics, Inc. | -0.0796 |
| Sarepta Therapeutics, Inc. | -0.2687 |
| Anixa Biosciences, Inc. | -0.0762 |
| Vicapsys Life Sciences, Inc. | -0.003 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 70.13M |
| Revenue (Quarterly) | 17.78M |
| Total Expenses (Quarterly) | -52.35M |
| Enterprise Value | 2.417B |
| Gross Profit Margin (Quarterly) | 73.66% |
| Earnings Yield | -9.65% |
| Normalized Earnings Yield | -9.651 |